This post was originally published on this site
https://i-invdn-com.akamaized.net/news/LYNXNPEC180BO_M.jpg
Regeneron Pharma announced earnings per share of $9.89 on revenue of $2.53B. Analysts polled by Investing.com anticipated EPS of $8.83 on revenue of $2.55B.
Regeneron Pharma shares are down 0.14% from the beginning of the year, still down 27.42% from its 52 week high of $664.64 set on July 20, 2020. They are under-performing the Nasdaq 100 which is up 4.77% from the start of the year.
Regeneron Pharma’s report follows an earnings beat by J&J on April 20, who reported EPS of $2.59 on revenue of $22.32B, compared to forecasts EPS of $2.34 on revenue of $21.98B.
Pfizer had beat expectations on Tuesday with first quarter EPS of $0.93 on revenue of $14.58B, compared to forecast for EPS of $0.7773 on revenue of $13.67B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar
